Sugi Predict

Sugi Predict / Targets / UTRN

UTRN

Utrophin · P46939 · UTRN on Sugi Atlas →

5,563 patent compounds predicted against UTRN, 1,721 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2245505 SCHEMBL2245505 1.00 20/20
SCHEMBL3949773 SCHEMBL3949773 1.00 20/20
SCHEMBL3953925 SCHEMBL3953925 1.00 20/20
SCHEMBL3714902 SCHEMBL3714902 0.68 20/20
SCHEMBL3714900 SCHEMBL3714900 0.65 20/20
SCHEMBL3643735 SCHEMBL3643735 0.60 12/20
SCHEMBL2244903 SCHEMBL2244903 0.53 12/20
Ezutromid Ezutromid (SCHEMBL3954452) 0.84 11/20
SCHEMBL3947253 SCHEMBL3947253 0.77 11/20
SCHEMBL3945381 SCHEMBL3945381 0.67 11/20
SCHEMBL3953365 SCHEMBL3953365 0.62 11/20
SCHEMBL3947228 SCHEMBL3947228 0.61 11/20
SCHEMBL4227947 SCHEMBL4227947 0.53 11/20
Ezutromid Ezutromid (SCHEMBL732212) 1.00 10/20
SCHEMBL3944357 SCHEMBL3944357 0.71 10/20
SCHEMBL3953220 SCHEMBL3953220 0.65 10/20
SCHEMBL3643733 SCHEMBL3643733 0.60 10/20
SCHEMBL3944431 SCHEMBL3944431 0.77 9/20
SCHEMBL4037442 SCHEMBL4037442 0.77 9/20
SCHEMBL2247868 SCHEMBL2247868 0.59 9/20

Clinical trials — most relevant to UTRN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) PHASE2/PHASE3RECRUITING
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy PHASE2UNKNOWN
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy PHASE1/PHASE2UNKNOWN
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients PHASE1/PHASE2UNKNOWN
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 PHASE1/PHASE2RECRUITING
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 PHASE1/PHASE2RECRUITING
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy PHASE1/PHASE2UNKNOWN
Exploratory Study of NS-089/NCNP-02 in DMD PHASE1/PHASE2COMPLETED
Exploratory Study of NS-065/NCNP-01 in DMD PHASE1COMPLETED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Molecular Analysis of Patients With Neuromuscular Disease nanRECRUITING
DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies nanRECRUITING
Biomarker for Duchenne Muscular Dystrophy nanCOMPLETED
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
Prospective Becker-Heart-Study nanUNKNOWN
The Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy nanRECRUITING
Extracellular RNA Biomarkers of Myotonic Dystrophy nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD nanENROLLING_BY_INVITATION
Urinary Titin Biomarker in DMD nanRECRUITING
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy nanRECRUITING
Improvement of DIAgnostic and Phenotype-genotype Correlation Studies in Patients With MYOpathy Suspected of TITinopathy nanUNKNOWN
Research of Biomarkers in Duchenne Muscular Dystrophy Patients nanCOMPLETED
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping nanUNKNOWN
Effects of Posture and Quality of Life in Duchenne Muscular Dystrophy Children nanRECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UTRN binder may also engage these)

ProteinNameSimilarity
G3V7L1 — 1.000 G3V7L1 →
P11532 — 1.000 P11532 →
O97592 — 1.000 O97592 →
Q5GN48 — 1.000 Q5GN48 →
P11533 — 0.998 P11533 →
P11531 — 0.997 P11531 →
Q8NF91 — 0.996 Q8NF91 →
P11530 — 0.994 P11530 →
Q6ZWR6 — 0.994 Q6ZWR6 →
Q03001 — 0.993 Q03001 →
Q9VDW6 — 0.992 Q9VDW6 →
O60437 — 0.992 O60437 →
Q91ZU6 — 0.992 Q91ZU6 →
Q9R269 — 0.992 Q9R269 →
Q9QXZ0 — 0.991 Q9QXZ0 →
D3ZHV2 — 0.991 D3ZHV2 →
Q9TW65 — 0.991 Q9TW65 →
Q9QXS1 — 0.990 Q9QXS1 →
A0A8M2BID5 — 0.990 A0A8M2BID5 →
P30427 — 0.990 P30427 →
P10911 — 0.990 P10911 →
MACF1 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 0.989 landscape →
Q0KL02 — 0.988 Q0KL02 →
Q8WXH0 — 0.988 Q8WXH0 →
Q90640 — 0.988 Q90640 →
Q7SIG6 — 0.988 Q7SIG6 →
Q86YR7 — 0.988 Q86YR7 →
A0A8M9PQ61 — 0.987 A0A8M9PQ61 →
Q6ZWQ0 — 0.987 Q6ZWQ0 →
P97924 — 0.987 P97924 →